NO2694640T3 - - Google Patents

Info

Publication number
NO2694640T3
NO2694640T3 NO12767723A NO12767723A NO2694640T3 NO 2694640 T3 NO2694640 T3 NO 2694640T3 NO 12767723 A NO12767723 A NO 12767723A NO 12767723 A NO12767723 A NO 12767723A NO 2694640 T3 NO2694640 T3 NO 2694640T3
Authority
NO
Norway
Application number
NO12767723A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2694640T3 publication Critical patent/NO2694640T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO12767723A 2011-04-15 2012-04-05 NO2694640T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161475788P 2011-04-15 2011-04-15

Publications (1)

Publication Number Publication Date
NO2694640T3 true NO2694640T3 (cg-RX-API-DMAC7.html) 2018-03-17

Family

ID=45976556

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12767723A NO2694640T3 (cg-RX-API-DMAC7.html) 2011-04-15 2012-04-05

Country Status (30)

Country Link
US (5) US9260434B2 (cg-RX-API-DMAC7.html)
EP (3) EP2697227B1 (cg-RX-API-DMAC7.html)
JP (4) JP2014511876A (cg-RX-API-DMAC7.html)
KR (1) KR102164443B1 (cg-RX-API-DMAC7.html)
CN (2) CN105111210B (cg-RX-API-DMAC7.html)
AU (4) AU2012242871C1 (cg-RX-API-DMAC7.html)
BR (1) BR112013026494A2 (cg-RX-API-DMAC7.html)
CA (1) CA2833296C (cg-RX-API-DMAC7.html)
CL (1) CL2013002990A1 (cg-RX-API-DMAC7.html)
CO (1) CO6862146A2 (cg-RX-API-DMAC7.html)
CY (1) CY1117440T1 (cg-RX-API-DMAC7.html)
DK (2) DK2697227T3 (cg-RX-API-DMAC7.html)
ES (2) ES2569665T3 (cg-RX-API-DMAC7.html)
HK (1) HK1256355A1 (cg-RX-API-DMAC7.html)
HR (2) HRP20160369T1 (cg-RX-API-DMAC7.html)
HU (2) HUE038586T2 (cg-RX-API-DMAC7.html)
IL (3) IL228862A (cg-RX-API-DMAC7.html)
LT (1) LT3018132T (cg-RX-API-DMAC7.html)
ME (1) ME02417B (cg-RX-API-DMAC7.html)
MX (1) MX340442B (cg-RX-API-DMAC7.html)
NO (1) NO2694640T3 (cg-RX-API-DMAC7.html)
NZ (2) NZ708090A (cg-RX-API-DMAC7.html)
PE (2) PE20141124A1 (cg-RX-API-DMAC7.html)
PL (2) PL2697227T3 (cg-RX-API-DMAC7.html)
PT (1) PT3018132T (cg-RX-API-DMAC7.html)
RS (2) RS54723B1 (cg-RX-API-DMAC7.html)
RU (2) RU2017107026A (cg-RX-API-DMAC7.html)
SI (2) SI2697227T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600130B (cg-RX-API-DMAC7.html)
WO (1) WO2012142237A1 (cg-RX-API-DMAC7.html)

Families Citing this family (285)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (cg-RX-API-DMAC7.html) 2011-04-15 2018-03-17
WO2013009701A2 (en) 2011-07-08 2013-01-17 The University Of North Carolina At Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
SG10201707545XA (en) * 2013-03-14 2017-10-30 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
SG11201507395PA (en) 2013-03-14 2015-10-29 Curadev Pharma Private Ltd Inhibitors of the kynurenine pathway
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN103382187B (zh) * 2013-08-06 2015-06-03 信实生物医药(上海)有限公司 一种3-氯-7(5)-溴苯并异恶唑的合成方法
EA032469B1 (ru) 2013-12-24 2019-05-31 Бристол-Маерс Сквибб Компани Новые трициклические соединения в качестве противораковых средств
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
SG11201700579XA (en) * 2014-09-05 2017-02-27 Merck Patent Gmbh Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
GB201418300D0 (en) * 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
HUE054526T2 (hu) 2014-10-29 2021-09-28 Bicyclerd Ltd MT1-MMP-ra specifikus biciklusos peptid ligandumok
ES2807182T3 (es) 2014-11-21 2021-02-22 Bristol Myers Squibb Co Anticuerpos frente a CD73 y sus usos
US10525035B2 (en) 2014-12-18 2020-01-07 Lankenau Institute For Medical Research Methods and compositions for the treatment of retinopathy and other ocular diseases
TW201630907A (zh) 2014-12-22 2016-09-01 必治妥美雅史谷比公司 TGFβR拮抗劑
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Tigitに対する抗体
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
CN105884828A (zh) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
AU2016226468B2 (en) 2015-03-02 2020-10-22 Bristol-Myers Squibb Company TGF-beta inhibitors
MX2017012729A (es) 2015-04-03 2017-11-15 Bristol Myers Squibb Co Inhibidores de indolamina 2,3-dioxigenasa (ido) para el tratamiento de cancer.
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
KR20170137165A (ko) * 2015-04-10 2017-12-12 베이진 엘티디 인돌아민 및/또는 트립토판 2,3-디옥시게나아제로서 신규한 5 또는 8-치환된 이미다조[1,5-a]피리딘
WO2016165613A1 (en) 2015-04-12 2016-10-20 Hangzhou Innogate Pharma Co., Ltd. Heterocycles useful as ido and tdo inhibitors
JP6971850B2 (ja) 2015-04-13 2021-11-24 ファイヴ プライム セラピューティクス インク がんの併用療法
AU2016250976B2 (en) * 2015-04-21 2020-02-27 Jiangsu Hengrui Medicine Co., Ltd. Imidazo isoindole derivative, preparation method therefor and medical use thereof
WO2016183114A1 (en) 2015-05-11 2016-11-17 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3307740B1 (en) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
RS63897B1 (sr) 2015-05-29 2023-02-28 Bristol Myers Squibb Co Antitela protiv ox40 i njihova primena
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN106256830B (zh) * 2015-06-18 2019-03-08 成都海创药业有限公司 一种氘代的ido抑制剂及其制备方法和用途
CA2990015A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
CN105037371A (zh) * 2015-06-30 2015-11-11 西华大学 一种氘代的吲哚胺-2,3-双加氧酶抑制剂
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
CA2992016C (en) 2015-07-24 2019-10-22 Newlink Genetics Corporation Salts and prodrugs of 1-methyl-d-tryptophan
US10399987B2 (en) 2015-07-28 2019-09-03 Bristol-Myer Squibb Company TGF beta receptor antagonists
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
KR20180042370A (ko) 2015-08-25 2018-04-25 브리스톨-마이어스 스큅 컴퍼니 Tgf 베타 수용체 길항제
CN106478634B (zh) * 2015-09-01 2020-05-22 尚华医药科技(江西)有限公司 稠合咪唑化合物、其制备方法、药物组合物和用途
US10308647B2 (en) 2015-10-29 2019-06-04 Scifluor Life Sciences, Inc. Fused imidazole derivatives as IDO/TDO inhibitors
MX2018005517A (es) 2015-11-02 2018-11-09 Five Prime Therapeutics Inc Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer.
CN108026565A (zh) * 2015-11-09 2018-05-11 豪夫迈·罗氏有限公司 用于鉴定ido1和/或tdo调节剂的筛选测定法
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
CA3004794A1 (en) 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
KR102738306B1 (ko) 2015-12-15 2024-12-03 브리스톨-마이어스 스큅 컴퍼니 Cxcr4 수용체 길항제
EP3394068B1 (en) * 2015-12-24 2024-09-11 Genentech, Inc. Tdo2 inhibitors
CN107056785B (zh) * 2016-01-02 2021-06-22 杭州英创医药科技有限公司 作为ido和tdo抑制剂的杂环化合物
WO2017134555A1 (en) 2016-02-02 2017-08-10 Emcure Pharmaceuticals Limited Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
CN112898309A (zh) * 2016-02-19 2021-06-04 正大天晴药业集团股份有限公司 作为免疫调节剂的三并环化合物
WO2017140272A1 (zh) * 2016-02-19 2017-08-24 正大天晴药业集团股份有限公司 作为免疫调节剂的三并环化合物
US11752131B2 (en) 2016-02-19 2023-09-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of obesity
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
CN105732643A (zh) * 2016-04-18 2016-07-06 苏州大学 一种偶联物、其制备方法及在制备ido酶抑制剂和非甾体抗炎药物中的应用
US10865244B2 (en) 2016-04-18 2020-12-15 Celldex Therapeutics, Inc. Nucleic acids encoding agonistic antibodies that bind CD40
CN107312005B (zh) * 2016-04-27 2021-12-17 上海翰森生物医药科技有限公司 具有ido/tdo抑制活性的稠合咪唑衍生物及其制备方法和应用
CN109414420A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
JP2019522627A (ja) 2016-05-04 2019-08-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
CN109414421A (zh) 2016-05-04 2019-03-01 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
JP2019516681A (ja) 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
EP3452451A4 (en) 2016-05-04 2019-11-13 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN107383012B (zh) * 2016-05-16 2021-09-28 鲁南制药集团股份有限公司 含二环的咪唑醇衍生物
CN107556316B (zh) * 2016-06-30 2021-11-12 鲁南制药集团股份有限公司 含桥环的咪唑衍生物
WO2017198159A1 (zh) * 2016-05-16 2017-11-23 鲁南制药集团股份有限公司 含桥环的咪唑衍生物
CN105902542A (zh) * 2016-05-16 2016-08-31 张阳 一种偶联物在制备治疗心血管疾病药物中的应用
CN106957318B (zh) * 2016-05-19 2019-12-10 中国科学院上海有机化学研究所 稠合多环吲哚啉化合物、其制备方法、药物组合物及应用
US11246877B2 (en) 2016-05-20 2022-02-15 The University Of Chicago Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof
AR108586A1 (es) 2016-06-10 2018-09-05 Lilly Co Eli Compuestos de 2,3-dihidro-1h-indol
CN107488179B (zh) * 2016-06-11 2024-06-07 鲁南制药集团股份有限公司 含桥环的咪唑醇衍生物
CN107556315B (zh) * 2016-06-30 2021-08-31 鲁南制药集团股份有限公司 含四元环的咪唑衍生物
EP4512829A3 (en) 2016-07-14 2025-06-11 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
CN107663159A (zh) * 2016-07-29 2018-02-06 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
WO2018028491A1 (zh) * 2016-08-09 2018-02-15 苏州国匡医药科技有限公司 吲哚胺2,3-双加氧酶抑制剂及其在药学中的用途
JP2019528300A (ja) 2016-08-26 2019-10-10 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company インドールアミン2,3−ジオキシゲナーゼの阻害剤およびその使用方法
WO2018045966A1 (zh) * 2016-09-12 2018-03-15 广州必贝特医药技术有限公司 含咪唑稠合三环类化合物及其应用
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ido及tdo調節之化合物及方法以及其適應症
EP3515914A4 (en) 2016-09-24 2020-04-15 BeiGene, Ltd. NEW IMIDAZO [1,5-A] PYRIDINES SUBSTITUTED IN POSITION 5 OR 8 AS INDOLEAMINE AND / OR TRYPTOPHANE 2,3-DIOXYGENASES
CA3037387A1 (en) 2016-10-13 2018-04-19 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
TW201815793A (zh) * 2016-10-21 2018-05-01 江蘇恆瑞醫藥股份有限公司 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法
WO2018072743A1 (zh) * 2016-10-21 2018-04-26 苏州盛迪亚生物医药有限公司 Pd-1抗体与ido抑制剂联合在制备抗肿瘤的药物中的用途
JP7096817B2 (ja) 2016-11-04 2022-07-06 オークランド ユニサービシーズ リミティド 三環式複素環式誘導体及びその使用
CN106474468B (zh) * 2016-11-23 2020-03-27 中国医学科学院医学生物学研究所 一种复合佐剂、含该复合佐剂的疫苗及疫苗的制备方法
WO2018106579A1 (en) * 2016-12-06 2018-06-14 Albert Einstein College Of Medicine, Inc. Drug targeting of human indoleamine 2,3-dioxygenase
EP3560928B1 (en) * 2016-12-20 2021-10-20 Shenzhen Chipscreen Biosciences Co., Ltd. Fused imidazole compound having indoleamine 2,3-dioxygenase inhibitory activity
SG10201911243WA (en) 2016-12-22 2020-02-27 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
CN108239091B (zh) * 2016-12-26 2021-08-13 中国医学科学院药物研究所 1-环己基-2-(5H-咪唑[5,1-a]异吲哚)乙基-1-酮的拆分
WO2018132279A1 (en) 2017-01-05 2018-07-19 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CN110191709A (zh) 2017-01-17 2019-08-30 德州大学系统董事会 可用作吲哚胺2,3-双加氧酶和/或色氨酸双加氧酶抑制剂的化合物
WO2018175954A1 (en) 2017-03-23 2018-09-27 F. Hoffmann-La Roche Ag Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
WO2018183608A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
US10570138B2 (en) 2017-04-21 2020-02-25 Kyn Therapeutics Indole AHR inhibitors and uses thereof
EP3628070B1 (en) 2017-04-28 2021-09-08 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides for use in increasing central memory t cells
WO2018209049A1 (en) 2017-05-12 2018-11-15 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107176956B (zh) * 2017-05-31 2019-11-12 成都海博锐药业有限公司 一种ido抑制剂化合物、药用组合物、用途
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP3645537A1 (en) 2017-06-28 2020-05-06 Genentech, Inc. Tdo2 and ido1 inhibitors
EP3645533B1 (en) 2017-06-28 2025-03-26 Genentech, Inc. Tdo2 and ido1 inhibitors
IL271601B2 (en) 2017-06-30 2024-05-01 Bristol Myers Squibb Co Amorphous and crystalline forms of ido inhibitors
KR102709265B1 (ko) 2017-07-28 2024-09-23 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
EP3638367A4 (en) 2017-08-02 2021-07-21 The University of Chicago NANOMETRIC ORGANOMETALLIC AND NANOPLAQUE ORGANOMETALLIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THESE
EP3661948B1 (en) 2017-08-04 2022-06-01 BicycleTx Limited Bicyclic peptide ligands specific for cd137
CN109983019B (zh) * 2017-08-08 2021-12-21 江苏恒瑞医药股份有限公司 一种咪唑并异吲哚类衍生物的制备方法
CN109384791B (zh) * 2017-08-09 2020-09-11 江苏恒瑞医药股份有限公司 一种咪唑并异吲哚类衍生物游离碱的晶型及其制备方法
JP7269917B2 (ja) 2017-08-17 2023-05-09 イケナ オンコロジー, インコーポレイテッド Ahr阻害剤およびその使用
JP7110325B2 (ja) 2017-08-17 2022-08-01 イドーシア ファーマシューティカルズ リミテッド インドールアミン 2,3-ジオキシゲナーゼ及び/又はトリプトファン 2,3-ジオキシゲナーゼの阻害剤
EP3670518A4 (en) 2017-08-18 2021-01-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TRICYCLIC COMPOUND CRYSTALS
WO2019040102A1 (en) * 2017-08-22 2019-02-28 Gilead Sciences, Inc. THERAPEUTIC HETEROCYCLIC COMPOUNDS
EP3676278B1 (en) 2017-08-31 2023-04-12 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP7316263B2 (ja) 2017-08-31 2023-07-27 ブリストル-マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
US10953032B2 (en) 2017-08-31 2021-03-23 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN107501272B (zh) * 2017-09-05 2020-03-31 中国药科大学 咪唑并异吲哚类ido1抑制剂、其制备方法及应用
EP3681498B1 (en) 2017-09-14 2022-10-05 Lankenau Institute for Medical Research Methods and compositions for the treatment of cancer
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
JP7366031B2 (ja) 2017-09-22 2023-10-20 カイメラ セラピューティクス, インコーポレイテッド タンパク質分解剤およびそれらの使用
US11203592B2 (en) 2017-10-09 2021-12-21 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
CN111344297B (zh) 2017-10-10 2023-10-20 百时美施贵宝公司 作为抗癌剂的环二核苷酸
US11427610B2 (en) 2017-10-16 2022-08-30 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019078246A1 (ja) 2017-10-19 2019-04-25 一般社団法人ファルマバレープロジェクト支援機構 Ido/tdo阻害剤
KR20200074214A (ko) 2017-11-01 2020-06-24 브리스톨-마이어스 스큅 컴퍼니 암을 치료하는데 사용하기 위한 면역자극 효능작용 항체
EP3707138B1 (en) 2017-11-06 2022-07-13 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
WO2019101188A1 (en) 2017-11-25 2019-05-31 Beigene, Ltd. Novel benzoimidazoles as selective inhibitors of indoleamine 2, 3-dioxygenases
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
KR102813744B1 (ko) 2017-12-27 2025-05-28 브리스톨-마이어스 스큅 컴퍼니 항-cd40 항체 및 그의 용도
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2019140229A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
ES2907282T3 (es) 2018-01-15 2022-04-22 Idorsia Pharmaceuticals Ltd Inhibidores de la indoleamina 2,3-dioxigenasa y/o de la triptófano dioxigenasa
WO2019141095A1 (zh) * 2018-01-19 2019-07-25 四川科伦博泰生物医药股份有限公司 脒类和胍类衍生物、其制备方法及其在医药上的应用
SG11202006701TA (en) 2018-01-29 2020-08-28 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
MX2020007797A (es) 2018-01-29 2020-09-18 Merck Patent Gmbh Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
SG11202007678QA (en) 2018-02-23 2020-09-29 Bicycletx Ltd Multimeric bicyclic peptide ligands
JP7250808B2 (ja) 2018-03-08 2023-04-03 ブリストル-マイヤーズ スクイブ カンパニー 抗がん剤としての環状ジヌクレオチド
US11149011B2 (en) 2018-03-20 2021-10-19 Plexxikon Inc. Compounds and methods for IDO and TDO modulation, and indications therefor
KR102874694B1 (ko) 2018-03-21 2025-10-23 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
TW202003565A (zh) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 抗mica及/或micb抗體及其用途
KR20200142542A (ko) 2018-04-12 2020-12-22 브리스톨-마이어스 스큅 컴퍼니 Cd73 길항제 항체 및 pd-1/pd-l1 축 길항제 항체에 의한 항암 조합 요법
CN112292128A (zh) 2018-04-16 2021-01-29 阿瑞斯医疗有限公司 Ep4抑制剂和其用途
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
CN112654621B (zh) 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
EA202190137A1 (ru) 2018-06-27 2021-05-17 Бристол-Маерс Сквибб Компани Нафтиридиноновые соединения для применения в качестве активаторов t-клеток
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
EP3820904A2 (en) 2018-07-09 2021-05-19 Five Prime Therapeutics, Inc. Antibodies binding to ilt4
CN121203021A (zh) 2018-07-11 2025-12-26 戊瑞治疗有限公司 在酸性pH下结合至VISTA的抗体
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase
WO2020023356A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12059420B2 (en) 2018-07-23 2024-08-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3846793B1 (en) 2018-09-07 2024-01-24 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
EP3858813A4 (en) * 2018-09-27 2022-06-22 Shenzhen Chipscreen Biosciences Co., Ltd. QUINOLONE DERIVATIVE WITH INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
PE20211284A1 (es) 2018-11-16 2021-07-19 Bristol Myers Squibb Co Anticuerpos anti-nkg2a y usos de los mismos
KR20250167680A (ko) 2018-11-30 2025-12-01 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
CN113453679B (zh) 2018-12-20 2025-07-08 C4医药公司 靶向蛋白降解
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Pd-l1に特異的な二環式ペプチドリガンド
CN113795264A (zh) 2019-03-19 2021-12-14 瓦尔希伯伦私人肿瘤研究基金会 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法
EP3946462A1 (en) 2019-04-02 2022-02-09 BicycleTX Limited Bicycle toxin conjugates and uses thereof
CA3135802A1 (en) 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
WO2020231713A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
CA3146406A1 (en) 2019-07-11 2021-01-14 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
US20220306630A1 (en) 2019-08-06 2022-09-29 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
JP2022547719A (ja) 2019-09-13 2022-11-15 ニンバス サターン, インコーポレイテッド Hpk1アンタゴニストおよびその使用
EP4031575A1 (en) 2019-09-19 2022-07-27 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
MX2022005839A (es) 2019-11-19 2022-06-09 Bristol Myers Squibb Co Compuestos utiles como inhibidores de la proteina helios.
CN115151306A (zh) 2019-11-26 2022-10-04 百时美施贵宝公司 (r)-n-(4-氯苯基)-2-((1s,4s)-4-(6-氟喹啉-4-基)环己基)丙酰胺的盐/共晶
PL4065582T3 (pl) 2019-11-26 2025-08-18 Ikena Oncology, Inc. Polimorficzne pochodne karbazolu i ich zastosowania
CN111333653A (zh) * 2019-12-16 2020-06-26 山东大学 一种icd诱导剂-ido抑制剂缀合物及制备方法与应用
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
IL294273A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted heteroaryl compounds are useful as t-cell activators
EP4081513B1 (en) 2019-12-23 2024-11-20 Bristol-Myers Squibb Company Substituted quinolinonyl piperazine compounds useful as t cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
KR20220120624A (ko) 2019-12-23 2022-08-30 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 피페라진 유도체
AU2020415377A1 (en) 2019-12-23 2022-08-18 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as T cell activators
AU2020412780A1 (en) 2019-12-23 2022-07-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
EP4087874A1 (en) 2020-01-06 2022-11-16 HiFiBiO (HK) Limited Anti-tnfr2 antibody and uses thereof
US20230054718A1 (en) 2020-01-07 2023-02-23 Hifibio (Hk) Limited Anti-galectin-9 antibody and uses thereof
CN115279771B (zh) 2020-01-15 2025-03-21 缆图药品公司 Map4k1抑制剂
TW202146393A (zh) 2020-03-03 2021-12-16 美商皮克醫療公司 Eif4e抑制劑及其用途
WO2021183428A1 (en) 2020-03-09 2021-09-16 Bristol-Myers Squibb Company Antibodies to cd40 with enhanced agonist activity
KR20230005160A (ko) 2020-03-19 2023-01-09 카이메라 쎄라퓨틱스 인코포레이티드 Mdm2 분해제 및 이의 용도
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
EP4132971A1 (en) 2020-04-09 2023-02-15 Merck Sharp & Dohme LLC Affinity matured anti-lap antibodies and uses thereof
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2021247897A1 (en) 2020-06-03 2021-12-09 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
CN111803635B (zh) * 2020-06-17 2023-03-14 中国医学科学院基础医学研究所 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
MX2023001217A (es) 2020-07-30 2023-03-03 Kymera Therapeutics Inc Metodos de tratamiento de linfomas mutantes.
MX2023001707A (es) 2020-08-10 2023-05-04 Shanghai Xunbaihui Biotechnology Co Ltd Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas.
MX2023001588A (es) 2020-08-17 2023-05-03 Bicycletx Ltd Conjugados biciclo específicos para nectina-4 y usos de estos.
EP4228764A1 (en) 2020-10-14 2023-08-23 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
KR20230131189A (ko) 2020-12-02 2023-09-12 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
JP2024501207A (ja) 2020-12-16 2024-01-11 ゴッサマー バイオ サービシズ、インコーポレイテッド T細胞活性化剤として有用な化合物
JP2024503300A (ja) 2020-12-30 2024-01-25 カイメラ セラピューティクス, インコーポレイテッド Irak分解剤およびそれらの使用
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
CN117098757A (zh) 2021-02-02 2023-11-21 里米诺生物科学有限公司 Gpr84拮抗剂和其用途
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
WO2022169921A1 (en) 2021-02-04 2022-08-11 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
WO2022174253A1 (en) 2021-02-12 2022-08-18 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
CA3210553A1 (en) 2021-02-12 2022-08-18 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives for the treatment of cancer
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途
TW202245788A (zh) 2021-02-15 2022-12-01 美商凱麥拉醫療公司 Irak4降解劑及其用途
MX2023010371A (es) 2021-03-05 2024-02-12 Univ Basel Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb.
WO2022187856A1 (en) 2021-03-05 2022-09-09 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
WO2022192145A1 (en) 2021-03-08 2022-09-15 Blueprint Medicines Corporation Map4k1 inhibitors
WO2022197641A1 (en) 2021-03-15 2022-09-22 Rapt Therapeutics, Inc. 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
US12071442B2 (en) 2021-03-29 2024-08-27 Nimbus Saturn, Inc. Substituted pyrrolo[3,4-c]pyridines as HPK1 antagonists
WO2022212876A1 (en) 2021-04-02 2022-10-06 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
BR112023020410A2 (pt) 2021-04-05 2023-11-28 Bristol Myers Squibb Co Compostos de oxoisoindolina substituída por piridinila para tratamento de câncer
WO2022216644A1 (en) 2021-04-06 2022-10-13 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds
CA3214952A1 (en) 2021-04-09 2022-10-13 Silvana Marcel LEIT DE MORADEI Cbl-b modulators and uses thereof
WO2022221866A1 (en) 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2022236058A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
AR126442A1 (es) 2021-07-14 2023-10-11 Blueprint Medicines Corp Inhibidores de map4k1
AR126453A1 (es) 2021-07-15 2023-10-11 Blueprint Medicines Corp Inhibidores de map4k1
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス, インコーポレイテッド eIF4E阻害剤及びその使用
CN118103368A (zh) 2021-08-25 2024-05-28 皮克医疗公司 Eif4e抑制剂及其用途
AU2022378630A1 (en) 2021-10-29 2024-05-09 Kymera Therapeutics, Inc. Irak4 degraders and synthesis thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
JP2025504059A (ja) 2022-01-31 2025-02-06 カイメラ セラピューティクス, インコーポレイテッド Irakデグレーダー及びその使用
WO2023150186A1 (en) 2022-02-01 2023-08-10 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
CN119768393A (zh) 2022-05-25 2025-04-04 医肯纳肿瘤学公司 Mek抑制剂和其用途
KR20250057800A (ko) 2022-08-02 2025-04-29 리미널 바이오사이언시스 리미티드 헤테로아릴 카복스아마이드 및 관련 gpr84 길항제 및 이의 용도
WO2024028364A1 (en) 2022-08-02 2024-02-08 Liminal Biosciences Limited Aryl-triazolyl and related gpr84 antagonists and uses thereof
IL318576A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd Pyridoxine-substituted GPR84 antagonists and their uses
EP4568950A1 (en) 2022-08-08 2025-06-18 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
WO2024036101A1 (en) 2022-08-09 2024-02-15 Bristol-Myers Squibb Company Tertiary amine substituted bicyclic compounds useful as t cell activators
CR20250043A (es) 2022-08-11 2025-03-25 Hoffmann La Roche Derivados bicíclicos de tetrahidrotiazepina
WO2024033458A1 (en) 2022-08-11 2024-02-15 F. Hoffmann-La Roche Ag Bicyclic tetrahydroazepine derivatives
CN119768401A (zh) 2022-08-11 2025-04-04 豪夫迈·罗氏有限公司 双环四氢硫氮杂䓬衍生物
JP2025526727A (ja) 2022-08-11 2025-08-15 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 二環式テトラヒドロチアゼピン誘導体
WO2024112894A1 (en) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
CN116143726B (zh) * 2022-12-02 2024-09-06 广州市联瑞制药有限公司 一种环磷腺苷杂质的制备方法
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
KR20250019700A (ko) 2023-05-08 2025-02-10 브리스톨-마이어스 스큅 컴퍼니 치환된 페닐 옥사졸론 화합물
TW202509014A (zh) 2023-05-10 2025-03-01 美商纜圖藥品公司 GSK3α抑制劑及其使用方法
WO2024249540A1 (en) 2023-05-31 2024-12-05 Bristol-Myers Squibb Company Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
WO2024254227A1 (en) 2023-06-07 2024-12-12 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024263853A1 (en) 2023-06-23 2024-12-26 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
EP4615455A2 (en) 2023-06-23 2025-09-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
EP4568957A1 (en) 2023-09-02 2025-06-18 Bristol-Myers Squibb Company Substituted phenyl oxooxazolyl piperidine dione compounds
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
AR133800A1 (es) 2023-09-13 2025-11-05 Bristol Myers Squibb Co Compuestos de oxoisoindolinil piperidina-2,6-diona sustituida
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
US20250145590A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096490A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
CN119707950A (zh) * 2024-12-24 2025-03-28 无锡市南京大学锡山应用生物技术研究所 一种用于免疫蛋白靶向降解的嵌合体及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3476195D1 (en) 1983-05-18 1989-02-23 Ciba Geigy Ag Cyclohexanedione-carboxylic-acid derivatives having a herbicidal and plant growth regulating activity
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US6451840B1 (en) 1997-12-05 2002-09-17 Medical College Of Georgia Research Institute, Inc. Regulation of T cell-mediated immunity by tryptophan
US20030194803A1 (en) 2002-04-12 2003-10-16 Mellor Andrew L. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
WO2004093871A1 (en) 2003-03-27 2004-11-04 Lankenau Institute For Medical Research Novel methods for the treatment of cancer
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
WO2005074603A2 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
CN101212967A (zh) 2005-05-10 2008-07-02 因塞特公司 吲哚胺2,3-双加氧酶调节剂及其用法
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
ES2540561T3 (es) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
EP2137168B1 (en) 2007-03-16 2016-09-14 Lankenau Institute for Medical Research Novel ido inhibitors and methods of use thereof
DE102007020493A1 (de) 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Amid-Derivate
EP2227233B1 (en) * 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
EP2231656A1 (en) 2007-12-19 2010-09-29 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
CA2722159C (en) * 2008-04-24 2016-04-05 Newlink Genetics Corporation Substituted phenylimidazole compounds and their use as ido inhibitors
CN104042611B (zh) 2008-07-08 2019-05-14 因塞特控股公司 作为吲哚胺2,3-双加氧酶的抑制剂的1,2,5-噁二唑
ES2601226T3 (es) 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
NO2694640T3 (cg-RX-API-DMAC7.html) 2011-04-15 2018-03-17
EP2922847A1 (en) 2012-11-20 2015-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
SG11201507395PA (en) 2013-03-14 2015-10-29 Curadev Pharma Private Ltd Inhibitors of the kynurenine pathway
SG10201707545XA (en) 2013-03-14 2017-10-30 Newlink Genetics Corp Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
AU2014235750B2 (en) 2013-03-15 2018-05-17 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase (IDO)
CA2907178A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Ido inhibitors
MX2015017486A (es) 2013-07-01 2016-03-21 Squibb Bristol Myers Co Inhibidores de indolamina 2,3-dioxigenasa (dio).
CN105517999B (zh) 2013-07-11 2019-06-28 百时美施贵宝公司 Ido抑制剂

Also Published As

Publication number Publication date
CA2833296A1 (en) 2012-10-18
AU2012242871A1 (en) 2013-10-31
CL2013002990A1 (es) 2014-07-04
CN103547579A (zh) 2014-01-29
IL241846A0 (en) 2015-11-30
US20190225618A1 (en) 2019-07-25
KR20140059167A (ko) 2014-05-15
CY1117440T1 (el) 2017-04-26
AU2016277574B2 (en) 2018-04-19
US9260434B2 (en) 2016-02-16
MX340442B (es) 2016-07-08
IL246515B (en) 2018-08-30
CA2833296C (en) 2020-12-08
EP3348558A1 (en) 2018-07-18
PE20141124A1 (es) 2014-09-06
US20160002249A1 (en) 2016-01-07
WO2012142237A8 (en) 2012-11-22
AU2012242871A8 (en) 2013-11-21
AU2012242871B2 (en) 2014-09-11
SI2697227T1 (sl) 2016-06-30
US10233190B2 (en) 2019-03-19
PL3018132T3 (pl) 2018-05-30
CN103547579B (zh) 2017-02-15
RU2613579C2 (ru) 2017-03-17
AU2012242871C1 (en) 2017-02-02
AU2016277574A1 (en) 2017-01-12
NZ616457A (en) 2015-05-29
HK1256355A1 (en) 2019-09-20
EP3018132A1 (en) 2016-05-11
ES2660831T3 (es) 2018-03-26
HRP20180335T1 (hr) 2018-04-20
LT3018132T (lt) 2018-03-26
CN105111210A (zh) 2015-12-02
US20160362412A1 (en) 2016-12-15
NZ723271A (en) 2018-03-23
RS54723B1 (sr) 2016-08-31
DK2697227T3 (en) 2016-04-25
JP2014511876A (ja) 2014-05-19
RU2017107026A (ru) 2019-01-23
AU2018202706A1 (en) 2018-05-10
WO2012142237A1 (en) 2012-10-18
JP2016029092A (ja) 2016-03-03
HUE038586T2 (hu) 2018-10-29
IL241846A (en) 2016-06-30
EP3018132B1 (en) 2017-12-13
JP6145491B2 (ja) 2017-06-14
ME02417B (me) 2016-09-20
ES2569665T3 (es) 2016-05-12
KR102164443B1 (ko) 2020-10-12
CO6862146A2 (es) 2014-02-10
JP2017149769A (ja) 2017-08-31
IL228862A (en) 2015-10-29
EP2697227B1 (en) 2016-02-03
US9388191B2 (en) 2016-07-12
DK3018132T3 (en) 2018-03-12
US20140066625A1 (en) 2014-03-06
HK1223371A1 (en) 2017-07-28
MX2013012021A (es) 2014-07-10
RU2017107026A3 (cg-RX-API-DMAC7.html) 2019-01-23
PL2697227T3 (pl) 2016-09-30
SMT201600130B (it) 2016-07-01
HK1193822A1 (zh) 2014-10-03
PE20181023A1 (es) 2018-06-27
CN105111210B (zh) 2018-10-09
JP5837673B2 (ja) 2015-12-24
NZ708090A (en) 2016-12-23
JP2015061877A (ja) 2015-04-02
US20180118753A1 (en) 2018-05-03
RU2013150811A (ru) 2015-05-20
SI3018132T1 (en) 2018-04-30
HUE027316T2 (en) 2016-10-28
AU2014274564B2 (en) 2016-10-06
IL228862A0 (en) 2013-12-31
AU2014274564A1 (en) 2015-01-22
US9850248B2 (en) 2017-12-26
BR112013026494A2 (pt) 2016-12-27
PT3018132T (pt) 2018-03-09
EP2697227A1 (en) 2014-02-19
HRP20160369T1 (hr) 2016-06-03
RS56992B1 (sr) 2018-05-31

Similar Documents

Publication Publication Date Title
BR112013022641A2 (cg-RX-API-DMAC7.html)
BR112013031251A2 (cg-RX-API-DMAC7.html)
RU2017107026A3 (cg-RX-API-DMAC7.html)
BR112013024383A2 (cg-RX-API-DMAC7.html)
BR112013023185A2 (cg-RX-API-DMAC7.html)
BR112013026905A2 (cg-RX-API-DMAC7.html)
BR112013022995A2 (cg-RX-API-DMAC7.html)
BR112013017670A2 (cg-RX-API-DMAC7.html)
BR112013026744A2 (cg-RX-API-DMAC7.html)
BR112013023927A2 (cg-RX-API-DMAC7.html)
BR112013024365A2 (cg-RX-API-DMAC7.html)
BR112013028733A2 (cg-RX-API-DMAC7.html)
BR112013024588A2 (cg-RX-API-DMAC7.html)
BR112013031556A2 (cg-RX-API-DMAC7.html)
BR112013026790A2 (cg-RX-API-DMAC7.html)
BR112013032366A2 (cg-RX-API-DMAC7.html)
BR112013032380A2 (cg-RX-API-DMAC7.html)
BR112013032377A2 (cg-RX-API-DMAC7.html)
BR112013018949A2 (cg-RX-API-DMAC7.html)
BR112013026895A2 (cg-RX-API-DMAC7.html)
BR112013021637A2 (cg-RX-API-DMAC7.html)
BR112013023266A2 (cg-RX-API-DMAC7.html)
BR112013032392A2 (cg-RX-API-DMAC7.html)
BR112013025487A2 (cg-RX-API-DMAC7.html)
BR112013017878A2 (cg-RX-API-DMAC7.html)